The IMvigor010 trial showed that Signatera-guided treatment with Tecentriq improved disease-free survival and overall ...
TAR-200, a small drug-releasing implant, wiped out tumors in most patients with high-risk bladder cancer. Its slow, ...
Researchers say a new drug-delivery implant could help patients with hard-to-treat bladder cancer avoid losing their bladders — and stay cancer-free for years.
The TAR‑200 slow‑release bladder implant cleared tumours in 82% of patients with high‑risk non‑muscle‑invasive bladder cancer ...
The experts agreed that perioperative approaches in muscle-invasive bladder cancer continue to evolve. Ongoing data will ...
We read with interest the FUTURE study by Mohamed Abdel-Fattah and colleagues, which reported on the role and cost-effectiveness of urodynamic testing in women with refractory overactive bladder ...
We thank Manuela Tutolo and colleagues for commending the design of the FUTURE study and the robustness of its delivery, including the urodynamics quality control. We also thank Maurizio Serati and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback